Print

Active Biotech Year-End Report January-December 2007

2008-02-14

Comments from President and CEO Sven Andréasson:
"During the year, the US and European regulatory authorities approved laquinimod for Phase III and recruitment of patients could commence. Consequently, we passed an important milestone in the development of a safe and effective product. Together with four additional products in clinical phases, we thus strengthened Active Biotech's position as a company with a balanced and mature project portfolio."
For further information, please contact:
Sven Andréasson
President and CEO
Tel +46 (0)46-19 20 49
Cecilia Hofvander
Manager Corporate Communications
Tel +46 (0)46-19 11 22
Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel +46 (0)46-19 20 00
Fax +46 (0)46-19 20 50
This report is also available at www.activebiotech.com

pdfActive Biotech AB Year-end Report 2007



Back